Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.57 |
| ▸ | F2 | P00734 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.52 |
| ▸ | APLNR | P35414 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473726 | 0.90 | CXCR4 (0.55) | CALCRF2C5AR1APLNR | |
| SCHEMBL29473692 | 0.90 | OPRM1 (0.54) | F2OPRM1OPRD1C5AR1APLNR | |
| SCHEMBL30233449 | 0.89 | CALCR (0.58) | CALCRF2OPRM1OPRD1C5AR1 | |
| SCHEMBL30233337 | 0.88 | CALCR (0.60) | CALCRF2OPRM1OPRD1C5AR1 | |
| SCHEMBL30974276 | 0.86 | F2 (0.61) | CALCRF2OPRM1OPRD1C5AR1 | |
| SCHEMBL30617831 | 0.86 | F2 (0.58) | CALCRF2OPRM1OPRD1C5AR1 | |
| SCHEMBL29842938 | 0.86 | CALCR (0.58) | CALCRF2OPRM1OPRD1C5AR1 | |
| SCHEMBL16684358 | 0.86 | F2 (0.65) | CALCRF2OPRM1OPRD1APLNR | |
| SCHEMBL30233460 | 0.85 | CALCR (0.59) | CALCRF2OPRM1OPRD1C5AR1 | |
| SCHEMBL5580530 | 0.85 | APLNR (0.52) | CALCRF2C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137767-A1 | LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES | VIROMETIX AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | disclosed |
| US-12465633-B2 | Lipopeptide building blocks and synthetic virus-like particles | VIROMETIX AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2024-08-29 | — | — | US | disclosed |
| CN-110891592-B | Cyclic peptides for protection against respiratory syncytial virus | 维罗米蒂克斯股份公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4295866-A2 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Virometix AG (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-20230355737-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | VIROMETIX AG (CH) | 2023-11-09 | — | — | US | disclosed |
| EP-3638284-B1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIROMETIX AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| EP-4216992-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | DBV Technologies (FR) | 2023-08-02 | — | — | EP | disclosed |
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2023-06-20 | — | — | US | disclosed |
| WO-2022063990-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | DBV TECHNOLOGIES (FR) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIP, LNPEP, CSTB | CALCR 1035/4885F2 1923/4885OPRM1 4852/4885 |
| US-20260137767-A1 | LIPOPEPTIDE BUILDING BLOCKS AND SYNTHETIC VIRUS-LIKE PARTICLES | VSIR, LRBA, CD74 | CALCR 1715/4885F2 2727/4885OPRM1 3453/4885 |
| US-12465633-B2 | Lipopeptide building blocks and synthetic virus-like particles | VSIR, CXCL10, SGTA | CALCR 1543/4885F2 1701/4885OPRM1 3685/4885 |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIP, QPCT, QPCTL | CALCR 1486/4885F2 352/4885OPRM1 4534/4885 |
| US-20230355737-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | CUTA, RRP12, VAC14 | CALCR 4262/4885F2 752/4885OPRM1 4542/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | CALCR 2833/4885F2 406/4885OPRM1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.